997 EORTC nomograms for predicting recurrence, progression, overall and disease specific survival in non-muscle invasive Ta T1 bladder cancer patients treated with maintenance Bacillus Calmette-Guerin

2014 ◽  
Vol 13 (1) ◽  
pp. e997
Author(s):  
S. Cambier ◽  
R. Sylvester ◽  
M. Brausi ◽  
T. De Reijke ◽  
W. Oosterlinck ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Bacillus Calmette Guerin ◽  
Disease Specific Survival ◽  
Muscle Invasive ◽  
Disease Specific

Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 513-513 ◽  
Author(s):  
David Tomoaki Miyamoto ◽  
Ewan Gibb ◽  
Kent William Mouw ◽  
Yang Liu ◽  
Chin-Lee Wu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Genomic Profiling ◽  
Disease Specific Survival ◽  
Clinical Factors ◽  
Gene Set Enrichment ◽  
Muscle Invasive Bladder Cancer ◽  
Trimodality Therapy ◽  
Muscle Invasive ◽  
Bladder Sparing ◽  
Disease Specific

513 Background: Trimodality therapy with TURBT followed by chemoradiation is an acceptable alternative to cystectomy for muscle invasive bladder cancer (MIBC). Genomic profiling has demonstrated MIBC can be divided into molecular subtypes with differing responses to chemotherapy. We explored the utility of genomic data to select patients for bladder-sparing trimodality therapy. Methods: Transcriptome wide gene expression profiles were generated for 189 MIBC TURBT samples from patients treated with trimodality therapy at a single institution. Of these, 103 passed microarray QC. Molecular subtype and expression of bladder cancer genes were assessed for association with overall and disease-specific survival. Transcriptome wide differential expression analysis was used to explore gene set enrichment in trimodality therapy response groups. Results: The chemoradiation cohort (n = 103) had a median followup of 6.9 years for alive patients, and was classified into four subtypes: basal (n = 44), basal claudin-low (n = 12), infiltrated luminal (n = 17) and luminal tumors (n = 30). There was no significant difference in overall or disease-specific survival by subtype. However, higher expression of the luminal-associated PPARG was correlated with increased survival after adjusting for subtype and clinical factors (HR = 0.52, p = 0.002). In contrast, a p53 signature predicted worse survival after adjusting for clinical factors (HR = 1.92, p = 0.022). Elevated mRNA expression of the DNA damage repair gene MRE11 was associated with improved survival in the trimodality cohort (HR = 0.69, P = 0.031), consistent with its potential role as a predictive biomarker for radiation response. Gene set enrichment revealed differential regulation of immune pathways in trimodality therapy responders relative to non-responders, including enrichment of interferon gamma signaling (p = 0.01) and CXCL9 (p = 0.031), suggestive of an interplay between tumor immunologic microenvironment and response to chemoradiation. Conclusions: Transcriptional profiling of MIBC revealed gene signatures correlated with response to chemoradiation, suggesting the potential of genomics to guide use of trimodality therapy.

Sign in / Sign up

Export Citation Format

Share Document